D&E material biopsy - Medium 1-3 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Tissue after curettage/evacuation.

₹370₹529

30% OFF

D&E Material Biopsy - Medium 1-3 cm: Comprehensive Medical Test Guide

Why is it done?
- Test Purpose: Histopathological examination of tissue specimens obtained from dilation and evacuation (D&E) procedures, specifically analyzing tissue fragments measuring 1-3 cm in diameter to identify pathological changes, assess tissue viability, and detect abnormal cellular growth or pregnancy-related complications.
- Primary Indications: Evaluation of products of conception following miscarriage or pregnancy loss; assessment of molar pregnancy; detection of gestational trophoblastic disease; identification of incomplete abortion; evaluation of retained products of conception; screening for malignancy or neoplastic changes.
- Clinical Circumstances: Performed following spontaneous abortion, therapeutic abortion, or evacuation of abnormal pregnancy; typically ordered when there is clinical suspicion of complications or pathological abnormalities; commonly performed in obstetric and gynecological settings when tissue size ranges from 1-3 cm.
Normal Range
- Normal Findings: Products of conception consisting of chorionic villi, decidualized endometrium, and trophoblastic tissue appropriate for gestational age; absence of abnormal cellular proliferation; no evidence of malignancy; normal placental architecture consistent with expected pregnancy stage.
- Reference Values: Results are qualitative/descriptive rather than quantitative; normal range indicates benign histology with appropriate tissue components; negative result indicates no evidence of molar pregnancy, malignancy, or significant pathology.
- Result Interpretation: NEGATIVE/BENIGN: No abnormalities detected, normal pregnancy tissue components; POSITIVE/ABNORMAL: Presence of pathological findings requiring clinical intervention; SPECIMEN ADEQUACY: Classification based on tissue quality and diagnostic value (adequate, adequate for diagnosis, limited, or inadequate).
- Units of Measurement: Size designation: Medium (1-3 cm); microscopic analysis using standard histological staining; measurements in micrometers for cellular components.
Interpretation
- Normal/Benign Results: Products of conception with appropriate histology for gestational age; presence of chorionic villi and decidualized endometrium; normal trophoblastic differentiation; indicates intrauterine pregnancy with no concerning pathology; trophoblastic tissue appropriate for pregnancy stage.
- Molar Pregnancy (Hydatidiform Mole): Complete mole shows hydropic swelling of chorionic villi with trophoblastic proliferation and absence of fetal parts; partial mole demonstrates abnormal chorionic villi with fetal tissue present; both require close clinical follow-up and beta-hCG monitoring due to malignant transformation risk.
- Malignancy/Choriocarcinoma: Abnormal trophoblastic proliferation with invasion patterns; atypical cellular morphology; excessive mitotic activity; suggests gestational trophoblastic neoplasia requiring urgent oncological referral and chemotherapy consideration.
- Incomplete Abortion: Presence of retained fetal tissue or placental remnants; tissue architecture suggests incomplete evacuation; may require repeat evacuation or medical management to prevent complications.
- Non-viable/Degenerative Changes: Evidence of tissue autolysis, necrosis, or degeneration; absence of vital cellular features; indicates fetal demise prior to evacuation; confirms pregnancy loss diagnosis.
- Factors Affecting Results: Specimen fixation quality; tissue processing adequacy; staining technique; gestational age accuracy; clinical history completeness; prior medical treatments affecting tissue appearance; specimen fragmentation or degradation.
Associated Organs
- Primary Organs/Systems Involved: Uterus (primary site of pregnancy implantation); placenta and placental tissues; endometrium; reproductive system; endocrine system (via hCG production).
- Common Abnormal Conditions Detected: Molar pregnancy (complete and partial); gestational trophoblastic neoplasia; choriocarcinoma; invasive mole; retained products of conception; incomplete abortion; ectopic pregnancy tissue; spontaneous abortion; therapeutic abortion complications; abnormal placental development.
- Associated Diseases/Complications: Gestational trophoblastic disease; malignant trophoblastic tumors; preeclampsia/eclampsia (associated with molar pregnancy); disseminated intravascular coagulation; reproductive tract hemorrhage; uterine perforation; infection/sepsis from retained tissue; anemia from blood loss.
- Potential Complications: If abnormalities detected: need for continued hCG surveillance; potential requirement for chemotherapy in malignant cases; increased risk of future molar pregnancies; psychological impact of diagnosis; need for contraception and pregnancy postponement; hyperemesis gravidarum (if molar pregnancy diagnosed); thyroid dysfunction complications.
Follow-up Tests
- If Normal Results: Beta-hCG levels to confirm complete evacuation; repeat ultrasound if clinically indicated; hematology panel to assess for anemia; Rh status screening for potential D immunoglobulin administration.
- If Molar Pregnancy Detected: Serial beta-hCG monitoring (weekly until undetectable, then monthly for 6-12 months); pelvic ultrasound follow-up; chest X-ray (to screen for metastases); liver and kidney function tests; thyroid function tests; consideration of CT or MRI for surveillance; referral to gestational trophoblastic disease center; genetic testing to determine complete vs. partial mole.
- If Malignancy Detected: Urgent oncology referral; metastatic workup (chest imaging, CT/MRI, serum tumor markers); baseline hematology and chemistry panel; staging studies; chemotherapy initiation; intensified hCG surveillance; consideration of prognostic scoring systems.
- If Incomplete Evacuation/Retained Tissue: Repeat ultrasound to confirm retained tissue; consideration of repeat D&E, vacuum aspiration, or medical management with misoprostol; antibiotic therapy if infection suspected; complete blood count for anemia assessment; coagulation studies if heavy bleeding.
- Monitoring Frequency: Normal results: typically no further histopathological testing required unless clinical symptoms develop; Molar pregnancy: weekly hCG × 3, then monthly × 6-12 months; Malignancy: individualized based on chemotherapy response and staging; Retained tissue: repeat imaging within 1-2 weeks post-intervention.
- Related Complementary Tests: Beta-hCG quantification; pelvic transvaginal ultrasound; blood group and antibody screening; complete metabolic panel; thyroid stimulating hormone; immunohistochemistry for p57 protein; flow cytometry for ploidy analysis; DNA microsatellite analysis; chest imaging; abdominal/pelvic imaging.
Fasting Required?
- Fasting Requirement: NO - Fasting is not required for this histopathological biopsy test, as it is a tissue analysis performed on material obtained during a medical procedure rather than a blood test.
- Pre-Procedure Preparation: Patient may eat and drink normally before procedure; standard surgical/procedural preparation required as per facility protocol; informed consent documentation; verification of pregnancy status and dating; baseline vital signs assessment.
- Anesthesia Considerations: If general anesthesia planned: typically requires 6-8 hour pre-operative fast from solid foods and 2-4 hours from clear liquids per facility anesthesia protocols; if local/regional anesthesia: minimal fasting requirements.
- Medications: Continue regularly scheduled medications unless specifically instructed otherwise by physician; anticoagulants (warfarin, aspirin, DOAC) may require adjustment per protocol; discuss all medications with anesthesia team; inform of any drug allergies.
- Special Instructions: Arrange for responsible adult transportation post-procedure; wear comfortable, loose-fitting clothing; remove jewelry and metal objects; empty bladder before procedure; arrange childcare if needed; avoid smoking 24 hours before procedure if possible; notify staff of any recent illnesses or infections.
- Post-Procedure Care: Patient may resume normal diet immediately post-procedure unless otherwise instructed; maintain adequate hydration; rest as needed; take prescribed pain management; avoid sexual intercourse and tampon use per physician guidelines; report unusual bleeding, fever, or severe pain; follow wound care instructions if applicable; schedule follow-up appointment as directed.

How our test process works!